Version 1
: Received: 29 December 2023 / Approved: 3 January 2024 / Online: 4 January 2024 (05:41:54 CET)
How to cite:
Simopoulou, F.; Kyrgias, G.; Georgakopoulos, I.; Avgousti, R.; Armpilia, C.; Skarlos, P.; Softa, V.; Theodorou, K.; Zygogianni, A. Does Adaptive Radiotherapy for Head and Neck Cancer Have a Favorable Impact on Dosimetric, Clinical, and Toxicity Outcomes? A Review.. Preprints2024, 2024010258. https://doi.org/10.20944/preprints202401.0258.v1
Simopoulou, F.; Kyrgias, G.; Georgakopoulos, I.; Avgousti, R.; Armpilia, C.; Skarlos, P.; Softa, V.; Theodorou, K.; Zygogianni, A. Does Adaptive Radiotherapy for Head and Neck Cancer Have a Favorable Impact on Dosimetric, Clinical, and Toxicity Outcomes? A Review.. Preprints 2024, 2024010258. https://doi.org/10.20944/preprints202401.0258.v1
Simopoulou, F.; Kyrgias, G.; Georgakopoulos, I.; Avgousti, R.; Armpilia, C.; Skarlos, P.; Softa, V.; Theodorou, K.; Zygogianni, A. Does Adaptive Radiotherapy for Head and Neck Cancer Have a Favorable Impact on Dosimetric, Clinical, and Toxicity Outcomes? A Review.. Preprints2024, 2024010258. https://doi.org/10.20944/preprints202401.0258.v1
APA Style
Simopoulou, F., Kyrgias, G., Georgakopoulos, I., Avgousti, R., Armpilia, C., Skarlos, P., Softa, V., Theodorou, K., & Zygogianni, A. (2024). Does Adaptive Radiotherapy for Head and Neck Cancer Have a Favorable Impact on Dosimetric, Clinical, and Toxicity Outcomes? A Review.. Preprints. https://doi.org/10.20944/preprints202401.0258.v1
Chicago/Turabian Style
Simopoulou, F., Kiki Theodorou and Anna Zygogianni. 2024 "Does Adaptive Radiotherapy for Head and Neck Cancer Have a Favorable Impact on Dosimetric, Clinical, and Toxicity Outcomes? A Review." Preprints. https://doi.org/10.20944/preprints202401.0258.v1
Abstract
We performed electronic research for articles published in PubMed, MEDLINE, and ScienceDirect databases from January 2004 to January 2023. The systematic review of twenty (20) peer-reviewed articles about dosimetric parameters and eight (8) articles about clinical outcomes confirmed the dosimetric advantages of ART through better target coverage and Organs at Risk (OARs) sparing, with subsequent benefits on decreased toxicity and improved clinical outcome, specifically local control of the disease. ART replanning is a sustainable strategy for minimizing toxicity by improving normal tissue sparing. Furthermore, it enhances target volume coverage by correctly determining the specific amount of dose to be delivered to the tumor. In conclusion, this review confirms that ART benefits dosimetric, clinical/therapeutic, and toxicity outcomes.
Keywords
head and neck cancer; adaptive radiotherapy; intensity-modulated radiation therapy; anatomic changes; dosimetric changes; time of adaptation; clinical outcomes
Subject
Public Health and Healthcare, Primary Health Care
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
